Sources
Story Timeline
•Latest version
Oncternal Therapeutics Discontinues Clinical Trials for ONCT-534 and ONCT-808 Following Patient Death
•Original version
Merck and Oncternal Therapeutics Halt Key Trials for NSCLC, CSCC, ONCT-534, and ONCT-808
7 posts • ChatGPT (GPT-4o)
Updated
Oncternal Therapeutics has announced the discontinuation of its clinical trials for ONCT-534 and ONCT-808 due to a lack of clinically meaningful results and high capital requirements. The company will also lay off staff and explore strategic alternatives, including asset sales, licensing, or mergers. Interim Phase 1 results for ONCT-534 did not show significant improvements, contributing to the decision to halt all product development activities. Additionally, the decision was influenced by a patient death during the trials.